ClinicalTrials.gg
RecruitingNCT05960721RECORD-IIIUpdated Jul 27, 2023

Low-dose NOAC Versus GDMT After LAAO

An interventional study of Rivaroxaban 15mg and Aspirin 100mg in Atrial Fibrillation, sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-27.

Sponsored by Xijing Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4,220
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 45 studies testing rivaroxaban in Atrial Fibrillation — 8 open to participants now, 9 under way, none of them phase 3. Rivaroxaban · Atrial Fibrillation.

Planned enrollment
6th of 45
4,220 · median 150
Started
2023
with 3 others
No phase
4 of 45
2 open now
Registered
40th of 45
by date

Among the 45 studies testing rivaroxaban in Atrial Fibrillation, this one is the 6th largest by planned enrollment, is one of 4 that started in 2023, is one of 4 with no phase, and was the 40th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

8 of the 45 studies testing rivaroxaban in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing rivaroxaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

The increased risk of Atrial fibrillation (AF) regarding thromboembolic stroke is predominantly due to the formation and embolization of clots from within the left atrial appendage (LAA). Percutaneous left atrial appendage occlusion (LAAO) is a nonpharmacological strategy for stroke prevention in patients with AF. Data from randomized trials, including PROTECT-AF, PREVAIL, and Prague-17, have suggested that LAAO has comparable efficacy to warfarin or NOACs. Considering these results, LAAO was recommended by the American College of Cardiology (ACC) and European Society of Cardiology (ESC) guidelines as a non-pharmacological stroke prevention strategy for patients with NVAF who have contraindications or are unsuitable for OAC.

The PROTECT-AF and PREVAIL trials stipulated the use of standardized antithrombotic medications which were designed to minimize the risk of stroke, systemic embolism, or device-related thrombosis. This antithrombotic strategy was subsequently endorsed by the guidelines, briefly, patients with LAAO were discharged on warfarin and aspirin for 45 days post-LAAO, if there was no leak or a leak ≤5 mm under transesophageal echocardiography (TEE) at 45-day follow-up, antithrombotic strategies shall switch to dual antiplatelet therapy (DAPT) until 6 months post-LAAO, and then aspirin thereafter.

Although LAAO was recommended by medical societies, previous patient-level meta-analyses have implied that compared with oral anticoagulation, LAAO had significantly more ischemic strokes, suggesting the inability of LAAO to prevent an ischemic stroke from sources beyond LAA. Will a combined strategy of LAAO and OAC further reduce the risk of stroke? The investigators hypothesized that a long-term low dose-Rivaroxaban (10mg daily) post-LAAO might be a potent supplement to the residue risk of ischemic stroke.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Left atrial appendage occlusion
  • Anti-coagulation
  • Atrial Fibrillation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Non-valvular atrial fibrillation (NVAF) patients with successful left atrial appendage occlusion (LAAO)
  2. Eligible for guideline-directed anti-thrombotic therapy
  3. Able to understand and provide and comply with all study medications

Exclusion criteria

Exclusion Criteria:

  1. Under the age of 18
  2. Unable to give or currently participating in another trial and not yet at its primary endpoint
  3. Patient is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of according to local practice)
  4. Concurrent medical condition with a of less than two years
  5. Haemodynamical unstable
  6. Known to medications such as heparin, antiplatelet or anticoagulation drugs, or contrast
  7. Peridevice leak > 5mm as assessed immediately after LAAO or any other procedure-related complications
  8. Comorbidities other than atrial fibrillation that required long term use of anticoagulation (such as implanted mechanical valve)
  9. Percutaneous coronary intervention (PCI) within 1 year.
  10. The patient had or is planning to have any cardiac or non-cardiac interventional or surgical procedure within 30 days prior to or 60 days after the WATCHMAN device implant (e.g., PCI, cardioversion, cardiac surgery)
  11. Ongoing overt bleeding
  12. Previous stroke/ within 30 days of enrolment
  13. Symptomatic carotid artery disease
  14. Severe renal insufficiency (≤30ml/min/1.73m2)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
4,220 participants (estimated)

Study arms

  • Experimental
    Low-dose novel oral anti-coagulation (NOAC)-based anti-thrombotic therapy

    HAS-BLED\<3: Rivaroxaban 15 mg QD for 3 months, followed by Rivaroxaban 10 mg QD indefinitely HAS-BLED≥3: Rivaroxaban 10 mg QD for 3 months, followed by Rivaroxaban 2.5 mg bid indefinitely

    Drug: Rivaroxaban 15mg · Drug: Rivaroxaban 10mg · Drug: Rivaroxaban 2.5mg

  • Active comparator
    Guideline determined medication therapy (GDMT)

    HAS-BLED\<3: Rivaroxaban 15 mg QD + Aspirin 100mg QD for 3 months, then Aspirin 100mg QD indefinitely HAS-BLED≥3: Aspirin 100mg QD + Clopidogrel 75mg QD for 3 months, then Aspirin 100mg QD indefinitely

    Drug: Rivaroxaban 15mg · Drug: Aspirin 100mg · Drug: Clopidogrel 75mg

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of the composite endpoint of any death, any stroke, systemic embolism, and The Bleeding Academic Research Consortium (BARC)-defined 3 or 5 bleeding events

    Time frame: 24 months post randomization

Secondary outcomes

  1. Rate of the composite endpoint of any death, any stroke, systemic embolism, and BARC defined 3 or 5 bleeding events

    Time frame: 45 days, 6, 12 months (Time-to-event)

  2. Rate of the composite endpoint of any death, any stroke, systemic embolism

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  3. Rate of the BARC type 3 or 5 bleeding events

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  4. Rate of the composite endpoint of any death, any stroke, systemic embolism, myocardial infarction (MI)

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  5. Rate of any death

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  6. Rate of any stroke

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  7. Rate of systemic embolism

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  8. Rate of myocardial infarction (MI)

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  9. Rate of BARC type 2, 3 or 5 bleeding events

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  10. Rate of BARC type 2 bleeding events

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  11. Rate of BARC type 3 bleeding events

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  12. Rate of BARC type 5 bleeding events

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  13. Rate of GUSTO defined major bleeding and/or minor bleeding

    Global Use of Strategies to Open Occluded Arteries, (GUSTO) defined major bleeding and/or minor bleeding

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  14. Rate of TIMI defined major bleeding and/or minor bleeding

    Thrombolysis in Myocardial Infarction (TIMI) defined major bleeding and/or minor bleeding

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  15. Rate of ISTH defined major bleeding and/or clinically relevant minor bleeding

    International Society on Thrombosis and Haemostasis (ISTH) defined major bleeding and/or clinically relevant minor bleeding

    Time frame: 45 days, 6, 12, 24 months (Time-to-event)

  16. Rate of patient adherence to allocated medication

    Adherence is defined as the participant who uses the medication strategies in this trial achieving 80% of the time on the therapeutic range

    Time frame: 45 days, 6, 12, 24 months (Binary)

  17. Scores of the National Institutes of Health Stroke Scale (NIHSS) questionnaire

    The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.

    Time frame: 45 days, 6, 12, 24 months (Continuous)

  18. Scores of the Modified Rankin Scale (mRS)

    The Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 to 5. A separate category of 6 is usually added for patients who expire. The Modified Rankin Score (mRS) is the most widely used outcome measure in stroke clinical trials.

    Time frame: 45 days, 6, 12, 24 months (Continuous)

  19. Scores of the 5-level EQ-5D version (EQ-5D-5L) questionnaire

    The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    Time frame: 45 days, 6, 12, 24 months (Continuous)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jul 2025, 24 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 24 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2023
First posted
Jul 27, 2023
StartActual
Jul 6, 2023
Primary completionEst.
Jul 30, 2025
CompletionEst.
Jul 30, 2028
Last update
Jul 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05960721
Lead sponsor
Xijing Hospital
Responsible party
LingTao (Professor in Cardiology, Director of the department of Cardiology, Xijing Hospital) — Principal investigator
First posted
Jul 27, 2023
Start date
Jul 6, 2023
Primary completion
Jul 30, 2025 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Jul 27, 2023

Study contacts

Chao Gao, M.D., Ph.D.
Contact
woshigaochao@gmail.com
+86-18629551066
Ruining Zhang, BSc
Contact
ruining-zhang@qq.com
+86-15802990370
Ling Tao, M.D., Ph.D.
study chair · Xijing Hospital
Chao Gao, M.D., Ph.D.
study chair · Xijing Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion